Stockscreener 앱 받기
2.15
1.60%
-0.035
전일 마감가:
$2.185
열려 있는:
$2.182
하루 거래량:
97,463
Relative Volume:
2.21
시가총액:
$7.91M
수익:
-
순이익/손실:
$2.81M
주가수익비율:
-0.1498
EPS:
-14.3497
순현금흐름:
$7.14M
1주 성능:
+6.44%
1개월 성능:
+4.37%
6개월 성능:
-27.61%
1년 성능:
-42.29%
1일 변동 폭
$2.10
$2.25
1주일 범위
$2.01
$2.25
52주 변동 폭
$1.7645
$4.18
Kiora Pharmaceuticals Inc Stock (KPRX) Company Profile
명칭
Kiora Pharmaceuticals Inc
전화
858-224-9600
주소
169 SAXONY RD., ENCINITAS
KPRX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KPRX
Kiora Pharmaceuticals Inc
|
2.15 | 8.04M | 0 | 2.81M | 7.14M | -14.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
463.86 | 119.17B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
796.55 | 84.19B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
398.29 | 52.77B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
788.49 | 48.98B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
175.97 | 36.31B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kiora Pharmaceuticals Inc 주식(KPRX)의 최신 뉴스
Will Kiora Pharmaceuticals Inc. stock deliver better than expected guidanceMarket Movers & Weekly Stock Performance Updates - ulpravda.ru
Will Kiora Pharmaceuticals Inc. (7EY) stock announce a stock splitTrade Ideas & Risk Controlled Daily Plans - ulpravda.ru
Can Kiora Pharmaceuticals Inc. stock surprise with earnings upside2025 Technical Patterns & Weekly High Return Forecasts - ulpravda.ru
Why Kiora Pharmaceuticals Inc. (7EY) stock trades below fair valueJuly 2025 Closing Moves & Weekly Market Pulse Updates - ulpravda.ru
Is Kiora Pharmaceuticals Inc. stock supported by strong fundamentalsWeekly Trend Recap & Weekly Consistent Profit Watchlists - ulpravda.ru
Kiora Pharmaceuticals, Inc.Common Stock (NQ: KPRX - FinancialContent
Pyxis Oncology (NASDAQ:PYXS) versus Kiora Pharmaceuticals (NASDAQ:KPRX) Head to Head Contrast - Defense World
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading 1.5% Higher – What’s Next? - Defense World
Kiora Pharmaceuticals (KPRX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Aug Intraday: What momentum indicators show for CALX stockPortfolio Gains Summary & Fast Gain Stock Tips - moha.gov.vn
Will Kiora Pharmaceuticals Inc. stock reach all time highs in 2025Weekly Trade Review & Target Return Focused Stock Picks - Улправда
Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Weekly Stock Analysis & Free Risk Controlled Daily Trade Plans - Улправда
Will Kiora Pharmaceuticals Inc. stock rally after Fed decisionsJuly 2025 EndofMonth & Weekly Return Optimization Plans - Улправда
Is Kiora Pharmaceuticals Inc. stock overvalued by current metrics2025 Stock Rankings & Verified Momentum Stock Ideas - Улправда
How Kiora Pharmaceuticals Inc. stock reacts to bond yields2025 Volatility Report & Safe Entry Trade Reports - DonanımHaber
Why analysts upgrade Kiora Pharmaceuticals Inc. stockJuly 2025 Action & Free High Accuracy Swing Entry Alerts - Улправда
How Kiora Pharmaceuticals Inc. stock benefits from global expansionStock Surge & Free Growth Oriented Trading Recommendations - DonanımHaber
Can Kiora Pharmaceuticals Inc. stock deliver surprise earnings beatJuly 2025 Analyst Calls & Safe Entry Trade Signal Reports - Улправда
Kiora Pharmaceuticals Highlights Anticipated Clinical and Corporate Milestones for 2023; Webcast Now Available on Company Website - TMX Newsfile
Kiora Pharmaceuticals to Participate in Upcoming Investor Conferences - TMX Newsfile
Kiora Pharmaceuticals Receives Grant from Choroideremia Research Foundation to Fund Novel Clinical Trial Endpoints for Inherited Retinal Diseases; Approval Granted to Initiate Clinical Validation Study - TMX Newsfile
Kiora Pharmaceuticals Appoints Praveen Tyle, PhD, as New Chairman; Succeeds Paul Chaney Who is Retiring After Serving 17 Years - TMX Newsfile
Kiora Pharmaceuticals Announces Private Placement of up to Approximately $45 Million - TMX Newsfile
Kiora Pharmaceuticals and Théa Open Innovation Enter Strategic Agreement to Develop and Commercialize KIO-301 for the Treatment of Inherited Retinal Diseases; Total Deal Value of up to $301 Million includes $16 Million Upfront, up to $285 Million in Clini - TMX Newsfile
Aug Decliners: Is Kiora Pharmaceuticals Inc. stock a defensive play in 2025Swing Trade & Intraday High Probability Alerts - Улправда
The Biotech Tug-of-War: Is Kiora Pharmaceuticals Positioned to Ride the 2025 Commodity Wave? - FinancialContent
Kiora Pharmaceuticals Earnings Notes - Trefis
Aug Rallies: How geopolitical tensions affect Kiora Pharmaceuticals Inc stock2025 Bull vs Bear & Community Consensus Trade Signals - moha.gov.vn
Kiora Pharmaceuticals, Inc. (KPRX) AI-Powered Stock Analysis - Meyka
Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 0.5% – Should You Sell? - Defense World
Will Kiora Pharmaceuticals Inc. (7EY) stock beat Nasdaq index returnsQuarterly Trade Report & Proven Capital Preservation Methods - Newser
How Kiora Pharmaceuticals Inc. (7EY) stock reacts to new regulationsJuly 2025 Recap & Expert Approved Momentum Ideas - Newser
Is Kiora Pharmaceuticals Inc. (7EY) stock cheap vs fundamentalsJuly 2025 Intraday Action & Free AI Powered Buy and Sell Recommendations - Newser
Will Kiora Pharmaceuticals Inc. stock benefit from commodity prices2025 Technical Overview & Expert Verified Stock Movement Alerts - Newser
Kiora Pharmaceuticals receives new patent for KIO-100 formulations By Investing.com - Investing.com Nigeria
Kiora Pharmaceuticals receives new patent for KIO-100 formulations - Investing.com
Kiora Pharmaceuticals Granted U.S. Patent Covering Additional Formulations for the KIO-100 Family of Anti-Inflammatory Compounds - TMX Newsfile
What drives Kiora Pharmaceuticals Inc stock priceConsumer Goods Stocks & Free Daily Top Stock Picks for All Investors - earlytimes.in
Kiora Pharmaceuticals’ KIO-104: A Promising Treatment for Macular Edema? - MSN
What analyst consensus implies for Kiora Pharmaceuticals Inc. (7EY) stock2025 Market WrapUp & High Accuracy Trade Signal Alerts - newser.com
Can Kiora Pharmaceuticals Inc. stock resist sector downturnsMarket Activity Report & Daily Profit Focused Screening - newser.com
Can Kiora Pharmaceuticals Inc. stock resist market sell offsFed Meeting & Real-Time Chart Pattern Alerts - newser.com
Will Kiora Pharmaceuticals Inc. stock outperform growth indexes2025 Biggest Moves & AI Powered Market Entry Strategies - newser.com
Why Kiora Pharmaceuticals Inc. (7EY) stock signals breakout potentialTrade Exit Summary & Expert Curated Trade Ideas - newser.com
News impact scoring models applied to Kiora Pharmaceuticals Inc.Quarterly Investment Review & Entry and Exit Point Strategies - newser.com
How moving averages guide Kiora Pharmaceuticals Inc. trading2025 Price Momentum & AI Forecasted Entry and Exit Points - newser.com
Tools to monitor Kiora Pharmaceuticals Inc. recovery probabilityJuly 2025 Update & High Yield Stock Recommendations - newser.com
How to track smart money flows in Kiora Pharmaceuticals Inc.Gap Down & Weekly Market Pulse Alerts - newser.com
Will Kiora Pharmaceuticals Inc. continue its uptrendQuarterly Market Summary & Verified Momentum Stock Alerts - newser.com
Intraday pattern recognizer results for Kiora Pharmaceuticals Inc.2025 Geopolitical Influence & Expert-Curated Trade Recommendations - newser.com
Using data filters to optimize entry into Kiora Pharmaceuticals Inc.Earnings Growth Summary & Weekly Market Pulse Updates - newser.com
Kiora Pharmaceuticals Inc (KPRX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.90%
자본화:
|
볼륨(24시간):